**Title**

Frailty as a risk-stratification tool in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

**Permalink**

https://escholarship.org/uc/item/3fc380wg

**Journal**

Journal of frailty, sarcopenia and falls, 8(2)

**ISSN**

2459-4148

**Authors**

Sohal, Aalam
Chaudhry, Hunza
Kohli, Isha
et al.

**Publication Date**

2023-06-01

**DOI**

10.22540/jfsf-08-083

Peer reviewed

## Original Article

# Frailty as a risk-stratification tool in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS)

**Aalam Sohal[1]\*, Hunza Chaudhry[2]\*, Isha Kohli[3], Kirti Arora[4], Jay Patel[5], Nimrat Dhillon[6], Ishandeep Singh[4], Dino Dukovic[7], Marina Roytman[8]**

[1]Department of Hepatology, Liver Institute Northwest, Seattle, USA;

[2]Department of Internal Medicine, University of California, San Francisco, Fresno, USA;

[3]Department of Public Health, Icahn School of Medicine, Mount Sinai, New York, USA;

[4]Dayanand Medical College and Hospital, India;

[5]Department of Internal Medicine, Orange Park Medical Center, Orange Park, Florida, USA;

[6]Shri Guru Ram Das Medical College, India;

[7]Ross University School of Medicine, Barbados, USA;

[8]Department of Gastroenterology and Hepatology, University of California, San Francisco, Fresno, USA

\* Equal contribution

## Abstract

**Objectives**: The concept of frailty has gained importance, especially in patients with liver disease. Our study systematically investigated the effect of frailty on post-procedural outcomes in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS). **Methods**: We used National Inpatient Sample(NIS) 2016-2019 data to identify patients who underwent TIPS. Hospital frailty risk score (HFRS) was used to classify patients as frail (HFRS>=5) and non-frail (HFRS<5). The relationship between frailty and outcomes such as death, post-procedural shock, non-home discharge, length of stay (LOS), post-procedural LOS, and total hospitalization charges (THC) was assessed. **Results**: A total of 13,700 patients underwent TIPS during 2016-2019. Of them, 5,995 (43.76%) patients were frail, while 7,705 (56.24%) were non-frail. There were no significant differences between the two groups based on age, gender, race, insurance, and income. Frail patients had higher mortality (15.18% vs. 2.07%, p<0.001), a higher incidence of non-home discharge (53.38% vs. 19.08%, p<0.001), a longer overall LOS (12.5 days vs. 3.35,p<0.001), longer post-procedural stay (8.2 days vs. 3.4 days, p<0.001), and higher THC ($240,746.7 vs. $121,763.1, p<0.001) compared to the non-frail patients. On multivariate analysis, frail patients had a statistically significant higher risk of mortality (aOR-3.22, 95% CI-1.98- 5.00, p<0.001). **Conclusion**: Frailty assessment can be beneficial in risk stratification in patients undergoing TIPS.

**Keywords**: Cirrhosis, Emerging, Frailty, National Inpatient Sample, TIPS

## Introduction

Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established modality for decreasing portal hypertension[1]. It is used in patients with refractory variceal bleeding, refractory ascites, refractory hydrothorax, Budd-Chiari syndrome, and hepatorenal syndrome[2]. Patients undergoing TIPS are at increased risk of in-hospital mortality, with one study reporting mortality as high as 10.1%[3]. It has also been reported that the risk of mortality differs by the indication of TIPS[4]. In carefully selected candidates, TIPS is associated with improved survival and quality of life,

especially in patients with refractory ascites and variceal bleeding[5-6]. Due to the inherent risks and benefits associated with this procedure, proper patient selection is critical[7].

Multiple models have been developed to predict survival in patients undergoing TIPS. Model for the end-stage liver disease (MELD) and Child-Pugh classification has been shown to predict survival in patients undergoing TIPS[8-9]. These scores focus on several physiological parameters but fail to capture elements such as the physical conditioning of the patients. In recent years, frailty has gained importance, especially in patients with chronic liver disease. It has been reported that 17-49% of the patients with chronic liver disease are frail, defined using various scores, including LFI (liver frailty index), CFS (Clinical frailty scale), FFS (Fried Frailty Score), and SPPBT (short physical performance test)[10-15]. Some studies have reported that incorporating frailty into traditional risk assessment scores, such as MELD, can help predict worse outcomes[14].

Hospital Frailty risk score (HFRS) is another tool for frailty assessment developed by Gilbert et al. using electronic health hospital records[16]. This score was developed using ICD-10 codes of diseases overrepresented in frail patients. Each ICD-10 code was awarded one specific value proportional to how strongly they predicted frailty. This score has been studied in patients undergoing spinal surgery, acute pancreatitis, and endoscopy for gastrointestinal bleeding and has been shown to predict poor clinical outcomes[17-19]. This score has also been shown to predict worse outcomes in patients with chronic conditions such as inflammatory bowel disease and chronic pancreatitis[20-21].

Perioperative frailty is an important indicator of post-surgical outcomes[22]. A random-effect meta-analysis concluded that despite various definitions, frailty is associated with increased morbidity and mortality in patients undergoing surgeries[23]. Until now, no studies have implemented HFRS to assess frailty and its impact on patients undergoing TIPS. Our study aimed to systematically investigate the effect of frailty, defined using HFRS, on post-procedural outcomes in patients undergoing TIPS.

## Materials and methods

### Data source

The National Inpatient Sample (NIS) is maintained by the Healthcare Cost and Utilization Project (HCUP) of the Agency for Healthcare Research and Quality. It is the largest openly-accessible database of inpatient hospital stays in the United States[24]. It collects data from a 20% stratified sample of United States hospitals from 37 states and has been reliably used to estimate disease burden and outcomes. NIS contains data on 7 million unweighted and 35 million weighted hospitalizations annually. Each hospitalization is de-identified and maintained in the NIS as a unique entry with one primary discharge diagnosis and up to 39 secondary diagnoses. Each entry carries patient demographics, including age, sex, race, insurance status, primary and secondary procedures (up to

25), hospitalization outcomes, total charges, and LOS. Since the data is de-identified and publicly available, this study did not require IRB approval.

### Study population

Patients with a procedure code for TIPS were identified using the International Classification of Diseases, Clinical Modification-10th Revision (ICD-10-CM). We excluded patients who were missing data on demographics (n=830) and mortality(n=0) from the analysis and those less than 18 years of age (n=70). Patients were stratified into two groups - frail and non-frail, based on HFRS scores. The inclusion flow diagram is presented in Figure 1.

### Definition of frailty

Gilbert et al. developed HFRS using 109 ICD-10 codes, which were noted to be overrepresented in frail patients. Each ICD-10 code was awarded a specific value proportional to how strongly it predicted frailty. In their analysis, HFRS >5 was used to classify patients as frail. Scores below five were classified as non-frail. We used the same approach to classify patients.

### Study Variables

Data were collected on patient demographics (age, gender, race, insurance status, and income quartile), hospital characteristics (region, hospital size, the location of the hospital, and teaching status), and etiologies of liver diseases (alcohol-related liver disease, hepatitis B, hepatitis C, and non-alcoholic steatohepatitis (NASH). Data were also collected regarding the common indications of TIPS (ascites, hepatorenal syndrome, variceal bleeding, and Budd Chiari syndrome), Elixhauser comorbidities, and Elixhauser comorbidity index (ECI). ECI is a well-validated index based on ICD 10-CM codes meant to be used in large administrative data to predict mortality and hospital resource use[25]. Information regarding common interventions such as esophagogastroduodenoscopy (EGD) and blood transfusion was also collected.

### Study outcomes

The primary outcome assessed was the impact of frailty on inpatient mortality in patients undergoing TIPS. Secondary outcomes included non-home discharge, length of stay (LOS), post-procedural length of stay, and total hospitalization charges (THC). Post-procedural length of stay was calculated by subtracting the time to the procedure from LOS. Hospital charges are defined as the dollar amount a hospital charges for services before negotiating discounts with insurance companies.

## Statistical analysis

Hospital-level discharge weights provided by NIS were used to generate national estimates. Categorical variables

**Figure 1.** Inclusion flow diagram for the study population.

were compared using the chi-square, whereas an independent sample t-test was used for continuous variables. Logistic/ Linear regression analysis was used to identify the impact of frailty on outcomes in TIPS. Univariate logistic regression was done to identify the impact of variables on outcomes. A p-value of 0.1 was considered a cut-off to be included in the multivariate regression model. All the variables that met the criteria were included for multivariate logistic regression for categorical outcomes. Similarly, for continuous variables, univariate and multivariate linear regression was done. The unadjusted and adjusted odds ratio were calculated with a 95% confidence interval. A type I error of <0.05 was considered statistically significant. Data analysis was done using STATA 17.0 (Texas).

## Results

A total of 13,700 patients were included in the analysis. Of those, 5,995 (43.76%) patients were frail, while 7,705 (56.24%) were non-frail.

### Patient demographics

Majority of the patients in the frail group were aged between 45-64 years (57.3%), male (62.9%), White (71.5%), and had Medicare insurance (39.28%). There were no significant differences between the groups on gender, race, ace categories, insurance status, or income quartile. The results are presented in Table 1.

### Etiology and complications of liver disease

The incidence of alcohol-related liver disease and NASH was higher in frail patients when compared to non-frail patients. Frail patients also had higher rates of ascites, variceal bleeding, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome than non-frail patients. A complete list of liver disease etiologies and decompensations of liver disease is present in Table 2.

### Additional Comorbidities and interventions

Frail patients were noted to have a higher incidence of

**Table 1.** Patient characteristics, stratified by frailty.

| | Low Frailty score n(%) | High Frailty Score n(%) | P-Value |
|---|---|---|---|
| **Mean Age** | 57.2 (+/- 0.3) | 57.9 (+/-0.35) | 0.169 |
| **Age categories** | | | 0.31 |
| 18-45 | 1,100 (14.3) | 765 (12.8) | |
| 45-65 | 4,465 (58) | 3,435 (57.3) | |
| >65 | 2,140 (27.8) | 1,795 (30) | |
| **Sex** | | | 0.78 |
| Male | 4,805 (62.4) | 3,770 (62.9) | |
| Female | 2,900 (37.6) | 2,225 (37.1) | |
| **Race** | | | 0.52 |
| White | 5,515 (71.6) | 4,285 (71.5) | |
| African American | 265 (3.4) | 295 (4.9) | |
| Hispanic | 1,400 (18.2) | 1,010 (16.9) | |
| Asian/Pacific islander | 155 (2.01) | 125 (2.1) | |
| Native American | 125 (1.62) | 95 (1.6) | |
| Other | 245 (3.1) | 185 (3.1) | |
| **Insurance** | | | 0.72 |
| Medicare | 2,950 (38.29%) | 2,355 (39.28%) | |
| Medicaid | 1,885 (24.46%) | 1,555 (25.94%) | |
| Private | 2,235 (29.01%) | 1,585 (26.44%) | |
| Uninsured | 370 (4.80%) | 295 (4.92%) | |
| **Income** | | | 0.19 |
| Lowest quartile | 2,435 (31.6) | 2,115 (35.3) | |
| Second quartile | 2,065 (26.8) | 1,495 (24.9) | |
| Third quartile | 1,855 (24.1) | 1,335 (22.3) | |
| Highest quartile | 1,350 (17.5) | 1,050 (17.5) | |
| **Region** | | | 0.83 |
| Northeast | 1,320 (17.1) | 1,075 (17.9) | |
| Midwest | 1,590 (20.6) | 1,205 (20.1) | |
| South | 3,075 (39.9) | 2,455 (41) | |
| West | 1,720 (22.3) | 1,260 (21) | |
| **Hospital Location** | | | **0.02** |
| Rural | 125 (1.6) | 40 (0.67) | |
| Urban | 7,580 (98.4) | 5,955 (99.3) | |
| **Teaching status** | | | 0.68 |
| Non-Teaching | 750 (9.7) | 615 (10.3) | |
| Teaching | 6,955 (90.3) | 5,380 (89.7) | |
| **Hospital bed size** | | | **0.03** |
| Small | 510 (6.6) | 480 (8) | |
| Medium | 1,485 (19.3) | 1,360 (22.7) | |
| Large | 5,710 (74.1) | 4,155 (69.3) | |
| **Elixhauser comorbidities** | | | **<0.001** |
| 0 | 15 (0.2%) | 0 | |
| 1 | 325 (4.21%) | 15 (0.25%) | |
| 2 | 960 (12.46%) | 80 (1.33%) | |
| 3 or more | 6,405 (83.13%) | 5,900 (98.42%) | |

| Etiology of liver disease | Low Frailty score n(%) | High Frailty Score n(%) | P-Value |
|---|---|---|---|
| NASH | 1,775 (13) | 1,125 (18.8) | **0.01** |
| Alcohol-related liver disease | 3,400 (44.1) | 3,330 (55.6) | **<0.001** |
| Hepatitis B | 165 (2.1) | 110 (1.8) | 0.55 |
| Hepatitis C | 650 (8.4) | 500 (8.4) | 0.92 |
| Budd Chiari syndrome | 125 (1.6) | 65 (1.1) | 0.24 |
| **Complications of liver disease** | | | |
| Ascites | 4,935 (64.1) | 4,255 (71) | **<0.001** |
| Variceal bleeding | 2,040 (26.48) | 2,545 (42.5) | **<0.001** |
| Hepatorenal syndrome (HRS) | 140 (1.8) | 710 (11.8) | **<0.001** |
| Spontaneous bacterial peritonitis (SBP) | 105 (1.4) | 385 (6.4) | **<0.001** |
| Hepatic encephalopathy | 230 (3) | 775 (12.9) | **<0.001** |

**Table 2.** Etiology and complications of liver disease, stratified by frailty.

cardiac arrhythmias (11.1% vs. 7.6%, p-0.002), congestive heart failure (19.9% vs. 10%, p-<0.001), paralysis (0.6% vs. 0.1%, p-0.04), other neurological disorders (19% vs. 4.9%, p<0.001), renal failure (23.9% vs. 11.2%, p<0.001), and coagulopathy (64.2% vs. 40.8%, p<0.001) than non-frail patients. More than 80% of frail patients had fluid and electrolyte disorders. There was no statistically significant difference between the two groups in the incidence of obesity or cancer. The results of additional comorbidities are presented in supplementary Table 2. There was a higher incidence of additional interventions in frail patients than in non-frail patients. Frail patients had a higher incidence of blood transfusion (33.3% vs. 20.3%, p<0.001) and esophagogastroduodenoscopy (44.3% vs. 27.06%, p<0.001).

## Outcomes

1. **In-hospital mortality** - Total in-hospital mortality in the study population was 1,070 (7.8%). The mortality in non-frail patients was 160 (3.1%) compared to 910 (15.2%) in non-frail patients. There was a statistically significantly higher mortality risk than in non-frail patients (aOR-3.22, p<0.001). The results of the multivariate regression model are presented in Table 3.

2. **Shock following the procedure** - There were 200 (1.5%) patients who developed shock following the procedure. 155 (2.6%) frail patients and 45 (0.58%) non-frail patients developed shock following the procedure. Although no statistically significant association was noted, a trend towards a higher risk of shock in frail patients was noted (aOR-2.43, p-0.07).

3. **Non-routine discharge** - A total of 4,670 (34.1%) patients had non-routine discharge. 3,200 frail patients and 1,470 non-frail patients had a non-routine discharge. The data regarding their disposition is presented in

supplementary Table 2. After adjusting for confounding factors, frail patients had higher odds of non-routine discharge (aOR- 2.37, p<0.001).

4. **Length of stay (LOS)** - The mean LOS in frail patients was 12.52 (+/-0.38) days compared to 5.36 (+/-0.17) in non-frail patients. Frail patients were noted to have statistically significant longer LOS after adjusting for confounding factors (adj. coefficient- 3.13 days, p<0.001).

5. **Post-procedural LOS** - The mean post-procedural LOS in frail patients was 8.23 (+/- 0.3) compared to 3.43 (+/-0.12) in non-frail patients. Frail patients were also noted to have statistically significant longer post-procedural LOS after adjusting for confounding factors (adj. coefficient- 2.01 days, p<0.001).

6. **Total hospitalization charges** - The mean total hospitalization charge in frail patients was 240,746.7 (+/-7749.23) compared to 121,763.1 (+/-3439.25) in non-frail patients. Frail patients were also noted to have statistically significant higher total hospitalization charges after adjusting for confounding factors (adj. coefficient- $ 51,458.15, p<0.001).

## Discussion

Frailty has become an increasingly relevant topic and has been shown to predict clinical outcomes, especially in chronic liver disease[26,27]. Our study systematically investigated the impact of frailty using HFRS as a tool to predict outcomes in patients undergoing TIPS. Using nationally representative data from 13,700 patients undergoing TIPS, we found that HFRS is associated with higher in-hospital mortality and resource utilization.

Patients undergoing TIPS procedures are at an inherently higher risk of mortality, given the underlying conditions necessitating TIPS placement. Mortality in patients

| Categorical outcomes | Adjusted Odds Ratio | P- value | 95% Confidence Interval |
|---|---|---|---|
| In-hospital mortality | 3.22 | **<0.001** | 2.03-5.10 |
| Non-routine discharge | 2.37 | **<0.001** | 1.90-2.96 |
| Post-procedure shock | 2.43 | 0.070 | 0.93-6.37 |
| **Continuous outcomes** | **Adjusted Coefficient** | **p-value** | **95% Confidence Interval** |
| Length of stay | 3.13 | **<0.001** | 2.38-3.89 |
| Total charges | 51,458.15 | **<0.001** | 38372.02-65439.1 |
| Post-procedural LOS | 2.07 | **<0.001** | 1.48-2.76 |

**Table 3.** Results of the multivariate regression model in outcomes in patients undergoing TIPS, stratified by frailty.

undergoing TIPS between 1995 and 2012 was 12.3%. The mortality decreased from 13.5% before 2005 to 11.5% in 2013[28]. In our study using nationally representative data between 2016-2020, there was a 7% overall in-hospital mortality, likely reflecting improved post-procedural care and patient selection compared to earlier years.

Mahmud et al., in their study of 804 patients with cirrhosis undergoing non-transplant major surgery, reported that frailty, defined by HFRS, was associated with poor postoperative survival compared to non-frail patients[26]. Klein et al. reported frailty criteria such as unintended weight loss and low hand grip strength as prognostic factors for survival after liver transplantation[27]. Lai et al. measured frailty using Liver Frailty Index (LFI), using three performance-based tests (grip, chair stands, and balance)[29]. They reported that combining LFI with the subjective clinician assessment was more likely to predict waitlist mortality than either score alone. Mahmoud et al. reported frailty (measured by psoas muscle density) to be associated with mortality in cirrhotic patients undergoing TIPS[30]. In their study, frailty was associated with increased mortality when the patients had a mean follow-up of 29.9 months (+/-34.1)[30]. Our study provides insight that not only the long-term mortality is increased, but immediate survival is also worse in frail patients. In our study, non-frail patients undergoing TIPS procedures had 2.1% in-hospital mortality compared to 15% in frail patients. After adjusting for confounding factors, frail patients, defined by high HFRS, were at a 3.22 times higher mortality risk than non-frail patients. Our findings, combined with the above-mentioned prior results, support the need to incorporate frailty as a risk-stratification tool in patients with chronic liver disease undergoing invasive interventions. HFRS was initially developed to evaluate outcomes in elderly patients, however recent studies have noted its utility in evaluating outcomes among younger patients[19].

Goh et al., in their study of 189 patients, reported frailty, as measured by short physical performance battery (SPPB), to be associated with longer postoperative intensive care (ICU) stay and higher 30-day complication rates[31]. Another study by Spoletini et al. reported that the pre-transplant

CONUT score, calculated using serum albumin, cholesterol levels, and lymphocyte count, is an independent risk factor for a complicated post-LT course[32]. This score was developed to measure frailty in elderly patients and is beneficial in predicting the course after surgical procedures. In our study, the trend toward a higher risk of post-procedural shock was noted in frail patients, although these findings did not reach statistical significance (2.6% of frail patients versus 0.6% in non-frail patients, p=0.07). A higher post-procedural length of stay was also noted in the frail group compared to non-frail patients. Our findings support prior studies and emphasize that frailty predicts post-procedural adverse outcomes.

In our study, frail patients had $51,458 higher hospitalization charges and 3.13 days longer LOS than non-frail patients. This could be attributed to higher severity as evidenced by a higher incidence of decompensations and additional interventions, such as endoscopy and blood transfusion in frail patients. Furthermore, higher rates of post-procedural shock and care coordination required for a non-routine discharge in frail patients might also contribute to higher resource utilization. Our results align with the findings of a cross-sectional study in Germany, which concluded that the mean total 3-month cost of care of frail patients (€1616 - €3659) was more than non-frail patients (€642)[33]. An Italian 3-year observational cohort study established frailty, determined by CFS score, as an independent risk factor for not being discharged home[34]. They reported that patients in the "moderate-severe" frailty and "very severe" frailty groups had an increased likelihood of being discharged somewhere other than home by five-fold and six-fold, respectively. Our findings and previous studies emphasize that frailty is predictive of increased resource utilization without clear evidence of improved survival or other health outcomes.

We acknowledge that our study has several limitations. Our study relies on a large national database and is subject to observational data limitations. The NIS database does not include information required for physical assessment of frailty. Since the data only contains information on acute hospitalization episodes, we cannot follow patients

longitudinally and track readmissions; therefore, we cannot calculate 30-day and 90-day mortality. We did not stratify the patient based on their transplant or pregnancy status as the proportion of these patients was relatively lower. Additionally, the NIS database lacks variables needed to calculate prognostic scores, such as the MELD score or the Child-Pugh class. To account for this limitation, we used decompensations of liver disease as surrogate markers of severity. Since the data relies on ICD-10 codes, the possibility of miscoding errors could not be ruled out. To account for this limitation, we used ICD-10 codes that have been validated in prior studies[35-37]. The strengths of our study include the large patient size from across the country, which limits selection bias.

## Conclusion

Our study reported a strong association between frailty and adverse outcomes such as higher in-hospital mortality and resource utilization in patients undergoing TIPS. Since HFRS is an administrative score that can be cumbersome to use in clinical practice, we recommend that physicians use other user-friendly scores, such as the liver frailty index, to risk-stratify patients. We believe there is an urgent need to incorporate frailty into the pre-procedural risk assessment in patients undergoing TIPS. The objective assessment of frailty may help physicians, patients and families to engage in joint decision-making prior to proceeding with TIPS or other potentially high risk procedures and patients with advanced liver disease.

*Authors' contributions*

*Aalam Sohal, Hunza Chaudhry, Isha Kohli, Kirti Arora, Jay Patel, Nimrat Dhillon, Ishandeep Singh and Dino Dukovic planned the study, reviewed the literature, drafted the manuscript, revised it for important intellectual content, and were involved in the final approval of the version to be published. Marina Roytman revised the article for important intellectual content and was involved in the final approval of the version to be published. Aalam Sohal accepts responsibility for the integrity of data analysis.*

## References

1. Vizzutti F, Schepis F, Arena U, Fanelli F, Gitto S, Aspite S, et al. Transjugular intrahepatic portosystemic shunt (TIPS): Current indications and strategies to improve the outcomes. Internal and Emergency Medicine 2020;15(1):37–48.

2. Strunk H, Marinova M. Transjugular intrahepatic portosystemic shunt (TIPS): Pathophysiologic Basics, actual indications and results with review of the literature. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2018;190(08):701–11.

3. Trivedi PS, Rochon PJ, Durham JD, Ryu RK. National Trends and outcomes of transjugular intrahepatic portosystemic shunt creation using the nationwide inpatient sample. Journal of Vascular and Interventional Radiology 2016;27(6):838–45.

4. Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World Journal of Gastroenterology 2014;20(45):16996.

5. Nazarian GK, Ferral H, Bjarnason H, Castañeda-Zúñiga WR, Rank JM, Bernadas CA, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. American Journal of Roentgenology 1996;167(4):963–9.

6. Niekamp A, Kuban JD, Lee SR, Yevich S, Metwalli Z, McCarthy CJ, et al. Transjugular intrahepatic portosystemic shunts reduce variceal bleeding and improve survival in patients with cirrhosis: A population-based analysis. Journal of Vascular and Interventional Radiology 2020;31(9).

7. Ferral H, Patel NH. Selection criteria for patients undergoing transjugular intrahepatic portosystemic shunt procedures: Current status. Journal of Vascular and Interventional Radiology 2005;16(4):449–55.

8. Angermayr B. Child-pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003;52(6):879–85.

9. Schepke M, Roth F, Fimmers R, Brensing K-A, Sudhop T, Schild HH, et al. Comparison of meld, child-pugh, and Emory Model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. American Journal of Gastroenterology 2003;98(5):1167–74.

10. Van Jacobs AC. Frailty assessment in patients with liver cirrhosis. Clinical Liver Disease 2019;14(3):121–5.

11. Wang CW, Lebsack A, Chau S, Lai JC. The range and reproducibility of the liver frailty index. Liver Transplantation 2019;25(6):841–7.

12. Kremer WM, Nagel M, Reuter M, Hilscher M, Michel M, Kaps L, et al. Validation of the clinical frailty scale for the prediction of mortality in patients with liver cirrhosis. Clinical and Translational Gastroenterology 2020;11(7).

13. Singh S, Taneja S, Tandon P, Bansal A, Gorsi U, Roy A, et al. A comparison of different frailty scores and impact of frailty on outcome in patients with cirrhosis. Journal of Clinical and Experimental Hepatology 2022;12(2):398–408.

14. Deng Y, Lin L, Fan X, Cui B, Hou L, Zhao T, et al. Incorporation of frailty estimated by gait speed within meld-na and the predictive potential for mortality in cirrhosis. Therapeutic Advances in Chronic Disease 2020;11:204062232092202.

15. Skladany L, Drotarova Z, Vnencakova J, Jancekova D, Molcan P, Koller T. Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease. Croatian Medical Journal 2021;62(1):8–16.

16. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: An observational study. The Lancet 2018;391(10132):1775–82.

17. Acosta CJ, Goldberg D, Amin S. Evaluating the impact of frailty on periprocedural adverse events and mortality among patients with GI bleeding. Gastrointestinal Endoscopy 2021;94(3).

18. Hannah TC, Neifert SN, Caridi JM, Martini ML, Lamb C, Rothrock RJ, et al. Utility of the hospital frailty risk score for predicting adverse outcomes in degenerative spine surgery cohorts. Neurosurgery 2020;87(6):1223–30.

19. Acosta CJ, Amin S, Barkin JA. S83 frailty status as a novel risk stratification tool in patients with acute pancreatitis. American Journal of Gastroenterology 2021;116(1).

20. Qian AS, Nguyen NH, Elia J, Ohno-Machado L, Sandborn WJ, Singh S. Frailty is independently associated with mortality and readmission in hospitalized patients with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology 2021;19(10).

21. Sohal A, Chaudhry H, Kohli I, Gupta G, Singla P, Sharma R et al.

Hospital frailty risk score predicts worse outcomes in patients with chronic pancreatitis. Annals of Gastroenterology 2023 36,1-8.

22. Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, et al. Frailty as a predictor of surgical outcomes in older patients. Journal of the American College of Surgeons 2010;210(6):901–8.

23. Sandini M, Pinotti E, Persico I, Picone D, Bellelli G, Gianotti L. Systematic Review and meta-analysis of frailty as a predictor of morbidity and mortality after major abdominal surgery. BJS Open 2017;1(5):128–37.

24. Healthcare Cost and Utilization Project (HCUP). 2016-2020. Agency for Healthcare Research and Quality, Rockville, MD.

25. Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data. Medical Care 2017;55(7):698–705.

26. Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Frailty is a risk factor for postoperative mortality in patients with cirrhosis undergoing diverse major surgeries. Liver Transplantation 2021;27(5):699–710.

27. Klein CG, Malamutmann E, Latuske J, Tagay S, Dörri N, Teufel M, et al. Frailty as a predictive factor for survival after liver transplantation, especially for patients with meld≤15 - a prospective study. Langenbeck's Archives of Surgery 2021;406(6):1963–9.

28. Lee EW, Kuei A, Saab S, Busuttil RW, Durazo F, Han S-H, et al. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. World Journal of Gastroenterology 2016;22(25):5780.

29. Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. American Journal of Gastroenterology 2018;113(2):235–42.

30. Mahmoud K, Abdel Aal AK, Osman S, Massoud M, Bae S, Shoreibah M. 1120 assessment of risk factors for mortality with tips placement: Age or frailty. American Journal of Gastroenterology 2019;114(1).

31. Goh MJ, Kim J, Chang WH, Sinn DH, Gwak G-Y, Paik Y-H, et al. Pretransplant functional status predicts postoperative morbidity and mortality after liver transplantation in patients with cirrhosis. Gut Liver 2023; doi: 10.5009/gnl220337.

32. Spoletini G, Ferri F, Mauro A, Mennini G, Bianco G, Cardinale V, et al. Conut score predicts early morbidity after liver transplantation: A collaborative study. Frontiers in Nutrition 2022;8.

33. Bock J-O, König H-H, Brenner H, Haefeli WE, Quinzler R, Matschinger H, et al. Associations of frailty with health care costs – results of the Esther Cohort Study. BMC Health Services Research 2016;16(1).

34. Mazzola P, Buttò V, Elli S, Galluccio R, Domenici G, Stella V, et al. Frailty predicts failure to discharge patients home from a subacute-care unit: A 3-year Italian experience. Aging Clinical and Experimental Research 2021;34(1):95–103.

35. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: Application to administrative data. BMC Medical Informatics and Decision Making 2015;15(1).

36. Goldberg D, Lewis JD, Halpern SD, Weiner M, Lo Re V. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiology and Drug Safety 2012;21(7):765–9.

37. Sohal A, Chaudhry H, Dhaliwal A, Singla P, Gupta G, Sharma R, et al. Gender differences in esophageal variceal bleeding in the United States. Annals of Medicine 2022;54(1):2115–22.

**Supplementary Table 1.** ICD-10 codes used in the study.

| Complications of liver disease | |
| --- | --- |
| Bleeding Varices | I85.01, I85.11 |
| Spotaneous Bacterial Peritonitis | K65.2 |
| Ascites | R18, K71.51, K70.11, K70.31 |
| Hepaticencephalopathy | K7211, K7291, G934 |
| Hepatorenal Syndrome | K76.7 |
| **Liver Etiology** | |
| Hepatitis C | B17.1, B18.2, B19.2 |
| NASH | K75.81, K76.0 |
| Hepatitis B | B19.1, B16 , B18.1,B18.0 |
| Budd-Chiari Syndrome | I820 |
| **Procedures** | |
| Endoscopy | 0D917ZX,0D917ZX,0D918ZX,0D927ZX,0D928ZX,0D937ZX,0D938ZX,0D947ZX,0D948ZX, 0D957ZX,0D958ZX,0D967ZX,0D968ZX,0D977ZX,0D978ZX,0D987ZX,0D988ZX,0D997ZX, 0D938ZX,0D998ZX,0D9A7ZX,0D9A8ZX,0D9B7ZX,0D9B8ZX,0D9C4ZX,0D9C7ZX,0D9C8ZX», 0DB17ZX,0DB18ZX,0DB27ZX,0DB28ZX,0DB37ZX,0DB38ZX,0DB47ZX,0DB48ZX,0DB57ZX, 0DB58ZX,0DB67ZX,0DB68ZX,0DB77ZX,0DB78ZX,0DB97ZX,0DB98ZX,0DD18ZX,0DD28ZX, 0DD38ZX,0DD48ZX,0DD58ZX,0DD68ZX,0DD78ZX,0DD98ZX,0DDA8ZX,0DDB8ZX,0DDC8ZX, 0DJ08ZZ,0DJ68ZZ,06L34CZ,06L38CZ |
| TIPS | 06183J4, 06184J4,06183JY,06183DY |
| Pressor | 3E030XZ,3E033XZ,3E040XZ,3E043XZ,3E050XZ,3E053XZ,3E060XZ,3E063XZ |
| Mechanical Ventilation | 5A1935Z, 5A1945Z, 5A1955Z |
| ICU | Pressor + Mechanical Ventilation |
| **Co-morbidity** | **ICD 10 code** |
| Congestive heart failure | I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9, I43.x, I50.x, P29.0 |
| Cardiac arrhythmias | I44.1-I44.3, I45.6, I45.9, I47.x-I49.x, R00.0, R00.1, R00.8, T82.1, Z45.0, Z95.0 |
| Valvular disease | A52.0, I05.x-I08.x, I09.1, I09.8, I34.x-I39.x, Q23.0Q23.3, Z95.2, Z95.4 |
| Pulmonary circulation Disorders | I26.x, I27.x, I28.0, I28.8, I28.9 |
| Peripheral vascular disorders | I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9 |
| Hypertension, uncomplicated | I10.x |
| Hypertension, complicated | I11.x-I13.x, I15.x |
| Paralysis | G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0-G83.4, G83.9 |
| Other neurological disorders | G10.x-G 13.x, G20.xG22.x, G25.4, G25.5, G31.2, G31.8, G31.9, G32.x, G35.x-G37.x, G40.x, G41.x, G93.1, G93.4, R47.0, R56.x |
| Chronic pulmonary disease | I27.8, 127.9, J40.x-J47.x, J60.x-J67.x, J68.4, J70.1, J70.3 |
| Diabetes, uncomplicated | E10.0, E10.1, E10.9, E11.0, E11.1, E11.9, E12.0, E12.1, E12.9, E13.0, E13.1, E13.9, E14.0, E14.1, E14.9 |
| Diabetes, complicated | E10.2-E10.8, E11.2-E11.8, E12.2E12.8, E14.2-E14.8 E13.2-E13.8, |
| Hypothyroidism | E00.x-E03.x, E89.0 |
| Renal failure | I12.0, I13.1, N18.x, NI9.x, N25.0, Z94.0,Z49.0-Z49.2, |
| Liver disease | B18.x, I85.x, I86.4, I98.2, K70.x, K71.1, K71.3K71.5, K71.7, K72.xK74.x, K76.0, K76.2K76.9. Z94.4 |
| Peptic ulcer disease excluding bleeding | K25.7, K25.9, K26.7, K26.9, K27.7, K27.9, K28.7, K28.9 |
| AIDS/HIV | B20.x-B22.x, B24.x |
| Lymphoma | C81.x-C85.x, C88.x, C96.x, C90.0, C90.2 |
| Metastatic cancer | C77.x-C80.x |
| Solid tumor without metastasis | C00.x-C26.x, C30.x-C34.x, C37.x-C41.x, C43.x, C45.x-C58.x, C60.x-C76.x, C97.x |

**Supplementary Table 1.** *(Cont. from previous page)*

| | |
|---|---|
| Rheumatoid arthritis/ collagen vascular diseases | L94.0, L94.1, L94.3, M05.x, M06.x, M08.x, M12.0, M12.3, M30.x, M31.0-M31.3, M32.x-M35.x, M45.x, M46.1, M46.8, M46.9 |
| Coagulopathy | D65-D68.x, D69.1, D69.3-D69.6 |
| Obesity | E66.x |
| Weight loss | E40.x-E46.x, R63.4, R64 |
| Fluid and electrolyte disorders | E22.2, E86.x, E87.x |
| Blood loss anemia | D50.0 |
| Deficiency anemia | D50.8, D50.9, D51.x-D53.x |
| Alcohol abuse | F10, E52, G62.1, I42.6, K29.2, K70.0, K70.3, K70.9, T51.x, Z50.2, Z71.4, Z72.1 |
| Drug abuse | F11.x-F16.x, F18.x, F19.x, Z71.5. Z72.2 |
| Psychoses | F20.x, F22.x-F25.x, F28.x, F29.x, F30.2, F31.2, F31.5 |
| Depression | F20.4, F31.3-F31.5, F32.x, F33.x, F34.1, F41.2, F43.2 |

**Supplementary Table 2.** Elixhauser comorbidities, stratified by frailty.

| Comorbidities | Low Frailty score n(%) | High Frailty Score n(%) | p-value |
|---|---|---|---|
| Cardiac arrhythmias | 770 (10) | 1,190 (19.9) | **<0.001** |
| Congestive heart failure | 585 (7.6) | 665 (11.1) | **0.002** |
| Valvular disease | 240 (3.1) | 175 (2.9) | 0.78 |
| Pulmonary circulation disorder | 260 (3.4) | 245 (4.1) | 0.31 |
| Peripheral vascular disease | 250 (3.2) | 255 (4.3) | 0.17 |
| Hypertension, uncomplicated | 2,685 (34.9) | 1,705 (28.4) | **<0.001** |
| Paralysis | 10 (0.1) | 35 (0.6) | **0.04** |
| Other neurological disorders | 380 (4.9) | 1,140 (19) | **<0.001** |
| Chronic pulmonary disease | 1,160 (15.1) | 925 (15.4) | 0.78 |
| Diabetes, uncomplicated | 1,580 (20.5) | 805 (13.4) | **<0.001** |
| Diabetes, complicated | 1,365 (17.7) | 1,420 (23.7) | **<0.001** |
| Hypothyroidism | 940 (12.2) | 705 (11.8) | 0.73 |
| Renal failure | 860 (11.2) | 1,435 (23.9) | **<0.001** |
| Peptic ulcer disease, excluding bleeding | 155 (2) | 140 (2.3) | 0.57 |
| AIDS/HIV | 30 (0.4) | 30 (0.5) | 0.66 |
| Lymphoma | 55 (0.7) | 30 (0.5) | 0.48 |
| Metastatic cancer | 100 (1.3) | 65 (1.1) | 0.59 |
| Solid tumor (without metastasis) | 485 (6.3) | 365 (6.1) | 0.82 |
| Rheumatoid arthritis/collagen vascular disease | 180 (2.3) | 135 (2.3) | 0.88 |
| Coagulopathy | 3,140 (40.8) | 3,850 (64.2) | **<0.001** |
| Obesity | 1,255 (16.3) | 965 (16.1) | 0.9 |
| Malnutrition | 870 (11.3) | 1,625 (27.1) | **<0.001** |
| Fluid and electrocyte disorder | 1,730 (22.5) | 5,020 (83.7) | **<0.001** |
| Blood loss anemia | 275 (3.6) | 200 (3.3) | 0.74 |
| Deficiency anemia | 500 (6.5) | 400 (6.7) | 0.85 |
| Alcohol abuse | 3,495 (45.4) | 3,455 (57.6) | **<0.001** |
| Drug abuse | 360 (4.7) | 385 (6.4) | 0.04 |
| Psychoses | 65 (0.8) | 70 (1.2) | 0.39 |
| Depression | 940 (1.2) | 920 (15.4) | 0.02 |
| Hypertension, complicated | 935 (12.1) | 1,275 (21.3) | **<0.001** |